Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201347 | 0.85 | IDO1 (0.40) | MAPTGRM2ALDH1A1 | |
| SCHEMBL13139707 | 0.85 | TMEM97 (0.41) | MAPTCYP2C19CTSLCTSBCTSK | |
| SCHEMBL12810022 | 0.81 | CTSL (0.41) | MAPTCYP2C19CTSLCTSBCTSK | |
| SCHEMBL3469857 | 0.81 | CTSL (0.41) | MAPTCYP2C19CTSLCTSBCTSK | |
| SCHEMBL6153660 | 0.81 | CASP1 (0.42) | MAPTCYP2C19CTSLCTSBCTSK | |
| SCHEMBL20654338 | 0.76 | AKT1 (0.51) | MAPTCYP2C19AKT1LMNACASP1 | |
| SCHEMBL12914558 | 0.74 | CASP3 (0.48) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL12831196 | 0.74 | SMN1; SMN2 (0.43) | CYP1A2 | |
| SCHEMBL10201808 | 0.74 | SMN1; SMN2 (0.43) | CYP1A2 | |
| SCHEMBL16381874 | 0.74 | SMN1; SMN2 (0.43) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | MAPT 1662/4885CYP2C19 3087/4885CTSL 100/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | MAPT 1662/4885CYP2C19 3087/4885CTSL 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.